6.14
+0.38(+6.60%)
Currency In USD
| Previous Close | 5.76 |
| Open | 5.79 |
| Day High | 6.29 |
| Day Low | 5.71 |
| 52-Week High | 13.5 |
| 52-Week Low | 2.28 |
| Volume | 42,808 |
| Average Volume | 173,868 |
| Market Cap | 57.13M |
| PE | -1.78 |
| EPS | -3.44 |
| Moving Average 50 Days | 8.07 |
| Moving Average 200 Days | 5.39 |
| Change | 0.38 |
If you invested $1000 in Clene Inc. (CLNN) since IPO date, it would be worth $31.49 as of January 07, 2026 at a share price of $6.14. Whereas If you bought $1000 worth of Clene Inc. (CLNN) shares 5 years ago, it would be worth $43.42 as of January 07, 2026 at a share price of $6.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
GlobeNewswire Inc.
Dec 03, 2025 1:00 PM GMT
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8’s potential disease modifying ac
Clene to Provide CNM-Au8® ALS Program Update
GlobeNewswire Inc.
Dec 02, 2025 10:39 PM GMT
Webcast set for 8:30 a.m. ET on December 3rdSALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmac
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
GlobeNewswire Inc.
Nov 20, 2025 1:00 PM GMT
SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondria